Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1246

Nesvacumab

Home » Nesvacumab

Background of Nesvacumab

Nesvacumab is an Ang2 selective, human MAb that potently blocks signaling through the Tie2 receptor, inhibiting tumor angiogenesis and growth. In mouse xenograft models of human solid tumors, Nesvacumab inhibits tumor growth. Angiopoietin-2 (Ang2) is a 75-kDa protein expressed in endothelium that is localized to human chromosomes 8p23.1 and first defined at sites of vascular remodeling. Ang2 acts as an autocrine factor in supporting endothelial cell homeostasis and counteracts Ang1 to sensitize endothelium.

Specifications

Catalog Number:
KB-1246
Antibody Name:
Nesvacumab
Isotype:
Human IgG1, kappa
FC Muations:
Wild Type
Target:
ANG2
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20C to -80C; Stored at 2-8C for one month without detectable loss of activity.

Characterization

Application

References

  1. Kelley R K , Siu L L , Loon K V ,et al.Phase 1 first-in-human (FIH) study of nesvacumab (REGN910) a fully human and selective angiopoietin-2 (Ang2) monoclonal antibody (MAb): Results from hepatocellular carcinoma (HCC) cohort. J. Journal of Clinical Oncology, 2014, 32(15_suppl):2540-2540.
  2. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277: 55-60.
  3. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005; 97: 512-23.